RVL Pharmaceuticals plc (O1P.F)

0.0030 0.0000 (0.00%) At close: 08:31AM CEST

RVL Pharmaceuticals plc

400 Crossing Boulevard
Bridgewater, NJ 08807
United States
908 809 1300
https://www.rvlpharma.com

Sector(s): 
Industry: 
Full Time Employees: 125

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Brian A. Markison	Chairman, President, CEO & Principal Financial Officer	489.95k	N/A	1959
Mr. James D. Schaub	Executive VP & COO	342.69k	N/A	1982
Mr. Christopher A. Klein	General Counsel	342.69k	N/A	1964
Mr. Michael J. DePetris	Principal Accounting Officer	N/A	N/A	1977
Mr. Jarret Miller	Executive Vice President of Human Resources	N/A	N/A	N/A
Scott Schroppe	Secretary	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Corporate Governance

RVL Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.